

SATURDAY, NOVEMBER 24, 2018 08:30- 10:30, HALL A

SESSION: CANCER DETECTION and MONITORING

CHAIRS: FRITSCH H (USA) DIAMANDIS E (CANADA)

- **08:30–09:00 DUFFY MJ, PhD (IRELAND)**

Clinical Research Center, St Vincent's University Hospital and School of Medicine,
University College Dublin, Dublin

Cancer Screening: does it always decrease mortality

- **09:00-09:30 DIAMANDIS EP, MD, PhD, FRCP(C), FRSC, (CANADA)**

Hold'em for Life Chair in Prostate Cancer Biomarkers,
Head, Division of Clinical Biochemistry, Mount Sinai Hospital and University Health Network,
Department of Laboratory Medicine & Pathobiology, University of Toronto

Personalized Cancer Biomarkers

- **09:30-10:00 GION M, MD (ITALY)**

Director, Regional Center for Cancer Biomarkers, Venice
Editor in Chief, The International Journal of Biological Markers

State of the art and trends in the clinical use of Cancer Biomarkers

- **10:00-10:30 LOOIJENGA E, PhD (HOLLAND)**

Pathology Dep., Erasmus MC, Rotterdam, Zuid Holland.

(Epi) Genetic heterogeneity of human Germ Cell Cancers: clinical implications.

10:30-11:00 COFFEE, POSTERS, EXHIBITION

SATURDAY, NOVEMBER 24, 1100-1300, HALL A

SESSION: NEW PERSPECTIVES in DIAGNOSIS and THERAPY of PROSTATE CANCER 1

CHAIRS: ROOBOL M (HOLLAND) KARSTEN S (GERMANY)

- **11:00-11:30 ROOBOL MJ, MD, PhD (HOLLAND)**
Decision Making in Urology, Erasmus MC, University Medical Center, Rotterdam -
Biomarkers, imaging and clinical data: the combination is the key

- **11:30-12:00 KAGAN J, PhD, (USA)**
Program Director, Cancer Biomarkers Research Group
Division of Cancer Prevention, National Cancer Institute, NIH.
Verification of Prostate Cancer Genomic biomarkers at the Protein Level using SRM-MS.

- **12:00-12:30 CARSTEN S, MD (GERMANY)**
Urology Clinic, Charité University Hospital, Berlin

Prostate Cancer Biomarkers: PHI – a new marker

- **12:30-13:00 KULKARNI H, PhD, (GERMANY)**
Molecular Radiotherapy, Central Hospital, Bad Berka.

Personalized Molecular Radiotherapy of Neuroendocrine Tumors and Prostate Cancer: THERANOSTICS for Precision Oncology

13:00-13:45 LUNCH

13:45 - 14:30 KEY NOTE - ABBOTT AWARD LECTURE

YARDEN Y, PhD (ISRAEL)
Chair, Department of Biological Regulation,
Director, Dwek Institute for Cancer Therapy Research
Weizmann Institute of Science, Rehovot.

HER-2 and EGFR: Molecular mechanisms and roles in Cancer treatments

SATURDAY, NOVEMBER 24, 2018, 11:00-13:00, HALL B

SESSION: LIQUID BIOPSY

CHAIRS: CHECHLINSKA M (POLAND) HOLDENRIEDER S (GERMANY)

- **11:00-11:30 HOLDENRIEDER S, MD, PhD (GERMANY)**
Head, Institute of Laboratory Medicine, German Heart Center, Technical University, Munich

Liquid Biopsy and Precision Medicine – Hype or Hope?

- **11:30-12:00 DIEHL F, PhD (GERMANY)**
CEO Sysmex-Inostics GmbH, Hamburg

Cell-free tumor DNA testing: From clinical trials to clinical practice

- **12:00-12:30 WINTER C, MD, PhD (GERMANY)**
Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich,

Prognostic and predictive relevance of RNA profiles in Prostate Cancer

- **12:30-13:00 BRONKHORST A, PhD (GERMANY)**
Institute of Laboratory Medicine, German Heart Center, Technical University Munich

Biology and release of circulating nucleic acids into plasma and serum

13:00 – 13:45 LUNCH

13:45 – 14:30 KEY NOTE- ABBOTT AWARD LECTURE, HALL A

YARDEN Y, PhD (ISRAEL)

Chair, Department of Biological Regulation,
Director, Dwek Institute for Cancer Therapy Research
Weizmann Institute of Science, Rehovot.

HER-2 and EGFR: Molecular mechanisms and roles in Cancer treatments

SATURDAY, NOVEMBER 24, 2018, 14:30-19:00 HALL A

SESSION: BLADDER CANCER

CHAIRS: ECKE T (GERMANY) SANCHEZ-CARBAYO M (SPAIN)

- **14:30-14:45 ECKE T, MD (GERMANY)**
Urology Clinic, HELIOS Hospital, Bad Saarow.

Urinary based Tumor Markers in Bladder Cancer

- **14:45-15:00 ROGGISCH J, M.Sc (GERMANY)**
Institute of Pathology, HELIOS Hospital Bad Saarow, Germany

Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in invasive and non-invasive urothelial Bladder Cancer

- **15:00-15:30 KILTIE A, PhD (UK)**
Senior Clinical Group Leader/Honorary Consultant Clinical Oncologist
CRUK/MRC Oxford Institute for Radiation Oncology, Oxford

Predictive Biomarkers of radiotherapy response in Bladder Cancer

- **15:30-16:00 van RHIJN B, MD, PhD, FEBU (HOLLAND)**
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

Molecular Markers (FGFR3 mutation; p53 & Ki-67 expression) and Clinical Outcome of Radical Cystectomy for Bladder Cancer: A Multi-center, Multi-lab Study

- **16:00-16:15 GOLKA K, PhD (GERMANY)**
Leibniz Research Centre for Working Environment and Human Factors, Dortmund.

Interplay of four genetic high-risk variants for Urinary Bladder Cancer

- **16:15- 16:30 RABIEN A, PhD (GERMANY)**
Department of Urology, University Hospital Charité, Berlin.

Drosha and the Argonautes 1 and 2 as Potential Biomarkers for Urothelial Bladder Carcinoma: an Immunohistochemical Study

16:30-17:00 COFFEE, POSTERS, EXHIBITION

- **17:00-17:30 OEHR P, PhD, MPE (JAPAN)**
Honsha, Bio-Med-Pharma, Japan

Joint Assessment of Sensitivity/Specificity Curves (SS-ROC) and positive/negative predictive Values Curves (PV-ROC) Interrelation with Reference to clinical Studies of Bladder Cancer and simulated Pattern Analysis.

- **17:30-18:00 NAWROTH R, PhD (GERMANY)**
University Hospital Rechts der Isar, Technical University of Munich

Molecular response mechanisms to CDK4/6 inhibitors in Bladder Cancer involve Skp/Cullin/F-box (SCF) complexes that regulate MDM2 and Rb

- **18:00-18:30 MALMSTROM P, PhD (SWEDEN)**
University of Uppsala

UBC Rapid as a Marker for Bladder Cancer.

- **18:30-19:00 SANCHEZ-CARBAYO M, PhD (SPAIN)**
Faculty of Biological Sciences, Universidad Pontificia de Salamanca

Exploring predictive Biomarkers of BCG response in T1 high grade Bladder Cancer

SATURDAY, NOVEMBER 24, 14:30 – 16:30, HALL B

SESSION: EXTRACELLULAR VESICLES,

organized by the German Society of Extracellular Vesicles, GSEV

CHAIR: KRAMER-ALBERS EM, PhD (GERMANY)

Head, Extracellular Vesicles Group, Institute of Developmental and Neuro-Biology, University Mainz

- 14:30-15:00 HENDRIX A, PhD (GERMANY)

Head, Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, University Gent

Standardized analysis of extracellular vesicles in liquid biopsies

- 15:00-15:30 NAZARENKO I, PhD (GERMANY)

Head, Exosomes and Tumor Biology Group, Institute of Prevention of Infections and Hospital Hygenics, University Hospital Freiburg

New devices in nanotechnology for detection of extracellular vesicles in liquid biopsy

- 15:30-16:00 KAHLERT C, MD (GERMANY)

Head, Exosome Research Group, Department of Visceral, Thoracic and Vascular Surgery, University Hospital Dresden

Evaluation of circulating exosomes as diagnostic marker in Pancreatic Cancer

- 16:00-16:30 PFAFFL M, PhD (GERMANY)

Chair, Department of Animal Physiology & Immunology, Life Science Center Weihenstephan, Technical University Munich

Exosomal microRNA biomarkers signatures in clinical diagnostics

16:30- 17:00 COFFEE, POSTERS, EXHIBITION

SATURDAY, NOVEMBER 24, 17:00 – 19:00, HALL B

SESSION: STANDARDIZATION AND QUALITY ASSESSMENT

organized by the INSTAND e.V.

CHAIRS: HOLDENRIEDER S, MD, PhD (GERMANY)

HABERMANN J, MD, PhD (GERMANY)

- **17:00-17:30 WOJTALEWICZ N, PhD (GERMANY)**
INSTAND e.V., Düsseldorf.

Tumor marker EQA trials: Trends and considerations

- **17:30-18:00 UHLIG S, PhD (GERMANY)**
QuoData Quality and Statistics, Dresden, Berlin

New strategies for EQA design and evaluation

- **18:00-18:30 HABERMANN J, MD, PhD (GERMANY)**
Head, Section for Translational Surgical Oncology and Biobanking, Department of Surgery and
Director, Interdisciplinary Center for Biobanking-Lübeck (ICB-L), University of Lübeck,
President, ESBB (European, Middle Eastern and African Society for Biopreservation and Biobanking)

How can hospital-integrated-Biobanks support individualized medicine?

SUNDAY, NOVEMBER 25, 2018, 08:30-13:00 - HALL A

SESSION: BREAST CANCER

EARLY DETECTION, PREDICTION OF RESPONSE, NEW THERAPIES

CHAIRS: HARBECK N (GERMANY) SENKUS E (POLAND)

- **08:30-09:00 HARBECK N, MD, PhD (GERMANY)**

Head, Breast Center of Munich University

Individualized Biomarker-based therapy decisions in Early Breast Cancer

- **09:00-09:30 SENKUS E MD, PhD (POLAND)**

Department of Oncology & Radio-therapy, Medical University of Gdańsk, Poland

ESMO Guidelines for Breast Cancer

- **09:30-10:00 DUFFY J, PhD (IRELAND)**

School of Medicine, Clinical Research Centre, St Vincent's University Hospital, Dublin.

Mutant P53 in Breast Cancer: Biology, Biomarker and potential as a therapeutic target

- **10:00-10:30 OED M, PhD (GERMANY)**

BIONTECH DIAGNOSTICS

MAMMATYPER- a new innovative molecular *in vitro* diagnostic tool for Breast Cancer subtyping

10:30-11:00 COFFEE, POSTERS, EXHIBION

- **11:00- 11:30 NICOLINI A, MD (ITALY)**
Unit of Oncology 1, University Hospital of Pisa, Italy.

Serum Tumor Markers in the surveillance of asymptomatic women following surgery for primary Breast Cancer: unsolved questions

- **11:30- 12:00 BARAK V, PhD (ISRAEL)**
Head, Immunology Lab for Tumor Diagnosis, Hadassah-Hebrew University Medical Center, Jerusalem

Assessment of treatment response and early detection of metastases by Tumor Markers in Breast Cancer.

- **12:00-12:30 FOCKE C, PhD (GERMANY)**
Dietrich-Bonhoeffer-Clinic, Neubrandenburg.

Immunohistochemistry vs. m-RNA based intrinsic subtyping of primary Breast Cancer: Influence of the proliferation measurement method on concordance rate.

- **12:30- 12:45 BANYS M, PhD, (GERMANY)**
Department of Gynecology, Marien Hospital, Hamburg.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic Breast Cancer

- **12:45- 13:00 KARLIKOVA M, MD, PhD (CZECH REP.)**
Department of Immunochemistry, University Hospital and Faculty of Medicine, Plzen

Circulating Matrix Metalloproteinases as Biomarkers in Colorectal and Breast Cancers – a pilot study

13:00 – 13:45 LUNCH

13:45 -14:30 KEY NOTE LECTURE HALL A

- **PANTEL K, PhD (GERMANY)**
Head, Institute of Tumor Biology, University of Hamburg, Hamburg

Clinical applications of Circulating Tumor Cells as liquid biopsy in Cancer patients

SUNDAY, NOVEMBER 25, 2018, 08:30-10:30, HALL B

SESSION: ENT CANCERS

CHAIRS: FRIEDRICH RF (GERMANY) MEIROVITZ A (ISRAEL)

- **08:30 -09:00 FRIEDRICH RF, MD (GERMANY)**
ENT and Surgical Dep, University Hospital, Hamburg

Oral and maxillofacial tumors- diagnosis and management

- **09:00-09:30 MEIROVITZ A, MD (ISRAEL)**
Head, Focused & Stereotactic Radiotherapy Unit, Hadassah Medical Center, Jerusalem

New Immune therapies for ENT Cancers

- **09:30-09:45 FADRUS P, MD, PhD (CZECH REP)**
Department of Neurosurgery, University Hospital Brno, Czech Republic

Prediction potential of selected microRNAs in glioblastoma patients

- **09:45-10:00 BARAK V, PhD (ISRAEL)**
Head, Immunology Lab for Tumor Diagnosis, Hadassah -University Medical Center, Jerusalem.

MUC-13, a new Biomarker

- **10:00-10:30 BUENTZEL J, MD (GERMANY)**
ORL, Head and Neck Surgery, Suedharz-Klinikum Nordhausen gGmbH, Nordhausen.

Combination of Photodiagnosis (PD) and Photodynamic Therapy (PDT) in Head Neck Cancer Patients

10:30-11:00 COFFEE, POSTERS, EXHIBION

SUNDAY, NOVEMBER 25, 2018, 11:00-13:00, HALL B

SESSION: NEW THERAPIES

CHAIRS: ARLEN P (USA) KEISARI Y (ISRAEL)

- **11:00-11:30 ARLEN P, MD (USA)**
President & Chief Executive Officer, Precision Biologics, Inc Medical Center, Rockville, MD

Novel approaches to deliver Chemotherapy through disruption of the Tumor Microenvironment.

- **11:30-12:00 AHMADZADEHFAR H, MD, MSc (GERMANY)**
University Hospital, Bonn

Theranostic Applications of Lutetium-177 in Nuclear Oncology

- **12:00-12:30 JANKET SJ, DMD, MPH (USA)**
Translational Oral Medicine, Forsyth Institute, Cambridge, MA

Does the microbiome affect the efficacy of cancer immunotherapy?

- **12:30-13:00 KEISARI Y, PhD (ISRAEL)**
Clinical Microbiology and Immunology Department, Sackler Faculty of Medicine, Tel Aviv University and Chief Biomedical Officer, Alpha Tau Medical LTD.

Ablation of tumors by a novel alpha-mediated radiotherapy can trigger a curative anti-tumor immunity

13:00 – 13:45 LUNCH

13:45 – 14:30 KEY NOTE LECTURE HALL A

- **PANTEL K, PhD (GERMANY)**
Head, Institute of Tumor Biology, University of Hamburg, Hamburg

Clinical applications of Circulating Tumor Cells as liquid biopsy in Cancer patients

SUNDAY, NOVEMBER 25, 2018, 14:30-18:30, HALL A

SESSION: OVARIAN CANCER

CHAIRS: JESCHKE U (GERMANY) ZEIMET AG (AUSTRIA)

- **14:30-15:00 FRITSCHKE H, PhD (USA)**

Past, Head of MD Anderson Hospital, Clinical Laboratory

Ovarian Cancer risk assessment in women with pelvic mass disease

- **15:00-15:30 JESCHKE U, MD (GERMANY)**

Head, Gynecology Department, Munich University

Expression and Function of Prostaglandin Receptors in Gynecologic Cancer

- **15:30-16:00 ZEIMET AG, MD (AUSTRIA)**

Past President of the Austrian AGO, Head, Division of Gynecologic Oncology,
Vice, Head, Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck

BioMarkers of Endometrium

- **16:00-16:30 KULASINGAM V, PhD (CANADA)**

Department of Laboratory Medicine & Pathobiology, University of Toronto

Using Omics to understand Ovarian Cancer pathogenesis

16:30-17:00 - COFFEE, POSTERS, EXHIBITION

- **17:00- 17:30 DOBERSTEIN K, PhD (USA)**

University of Pennsylvania

L1CAM for detection of Ovarian Cancer

- **17:30-18:00 CHECHLINSKA M, PhD (POLAND)**

Head, Department of Immunology, Maria Skłodowska-Curie Memorial Cancer Center,
University of Warsaw

Long non-coding RNAs in Ovarian Cancer

18:00-18:30

SUNDAY, NOVEMBER 25, 2018 14:30 – 16:30, HALL B

SESSION: TRANSLATIONAL BIOMARKERS APPROACHES - CESAR

organized by the Central European Society of Anticancer Drug Research

CHAIRS: KLOFT C, PhD (GERMANY) RITTER C, PhD (GERMANY)

- 14:30-15:00 BENDAS G, PhD (GERMANY)

Head, Institute of Pharmaceutic Chemistry, University of Bonn

Discovery of drug resistance mechanisms

- 15:00-15:30 RITTER C, PhD (GERMANY)

Head, Institute of Pharmacy, University of Greifswald

The use of systems pharmacology approaches to identify drug resistance networks

- 15:30-16:00 KLOFT C, PhD (GERMANY)

Head, Department of Clinical Pharmacy and Biochemistry, Free University, Berlin

Mathematic modelling of disease development and drug response

- 16:00-16:30 MEYER F, PhD (GERMANY)

Center for Internal Medicine, Oncology and Hematology, Friedrichshafen.

Individualized drug monitoring in the CEPAC-TDM lung cancer trial

16:30 – 17:00 COFFEE, POSTERS, EXHIBION

SUNDAY, NOVEMBER 25, 2018, 17:00-19:00 HALL B

SESSION: EGTM (EUROPEAN GROUP of TUMOR MARKERS)

CHAIRS: MOLINA R (SPAIN) BARAK V (ISRAEL)

- 17:00-17:30 MOLINA R, MD. PhD (SPAIN)

Head, Clinical Laboratory- OncoBiology Unit, Hospital Clinic, University of Barcelona

EGTM Lung Cancer Guidelines

- 17:30-18:00 PUIG S, MD (SPAIN)

Hospital Clinic, University of Barcelona

S-100 in the early diagnosis of Malignant Melanoma relapse

- 18:00-18:30 BARCO SANCHEZ A, MD (SPAIN)

Unidad de Bioquímica tumoral UGC, Bioquímica Clínica del Hospital Universitario Virgen Macarena de Sevilla

HE-4 alone and in combination with IOTA in the diagnosis of abdominal masses

EGTM DISCUSSIONS and DINNER

MONDAY, NOVEMBER 26, 2018 08:30-12:30 HALL A

SESSION: IMMUNO THERAPY

CHAIRS: ROMAGNANI S (ITALY) SELL S (USA)

- **08:30-09:00 SELL S, MD, PhD (USA)**
New York State Department of Health, Wadsworth Center

History of Cancer Immunotherapy.

- **09:00-09:30 ARLEN PM, MD (USA)**
President & Chief Executive Officer, Precision Biologics, Inc.
Medical Center, Rockville, MD

Design and Development of Novel Immunogenic Antibodies Targeting Neoantigens

- **09:30- 10:00 DIAMANDIS EP, MD, PhD, FRCP(C), FRSC, (CANADA)**
Hold'em for Life Chair in Prostate Cancer Biomarkers,
Head, Division of Clinical Biochemistry, Mount Sinai Hospital and University Health Network,
Department of Laboratory Medicine & Pathobiology, University of Toronto

Biomarkers for Cancer Immunotherapy

- **10:00-10:30 MORO R, MD (CANADA)**
PACIFIC Research Center, Richmond BC

The AFP Receptor (RECAF) as a marker for targeted Cancer therapy

10:30-11:00 COFFEE, POSTERS, EXHIBITION

- **11:00-11:30 JANKET SJ, DMD, MPH (USA)**
Translational Oral Medicine, Forsyth Institute, Cambridge, MA

Mechanisms and predictors of the immune Checkpoint Inhibitor therapy failure

- **11:30-12:00 FERRARI P, MD (ITALY)**
Unit of Oncology 1, University Hospital of Pisa

Immunotherapy for Breast Cancer

- **12:00-12:30 ROMAGNANI S, PhD (ITALY)**
Immunology Dep, Florence University

Resistance to Immunotherapy in Cancer patients

12:30- 13:00 ISOBM GA - GENERAL ASSEMBLY, HALL A

MONDAY, NOVEMBER 26, 2018 14:30-19:00, HALL A

SESSION: GASTRIC and CRC

CHAIRS: DUFFY M (IRELAND) CREE I (UK)

- **14:30-15:00 CREE I, PhD (UK)**
International Agency for Research on Cancer (IARC), World Health Organization (WHO).

Colorectal Cancer detection from blood

- **15:00-15:30 DUFFY M, PhD (IRELAND)**
Clinical Research Center, St Vincent's University Hospital and School of Medicine,
University College Dublin, Dublin

Biomarkers in Colorectal Cancer for today and tomorrow:

- **15:30-16:00 NIELSEN HJ, MD, PhD (DENMARK)**
Hvidovre Hospital, Copenhagen

Improved selection to colonoscopy by the triage concept

- **16:00-16:15 TOPOLCAN O, MD, PhD (CZECH REP)**
Head, Biochemical Division, University Hospital and Faculty of Medicine, Plzen.

Biomarkers and Liver Cancer process

- **16:15-16:30 PESTA M, MD (CZECH REP)**
Department of Biology, Faculty of Medicine and Charles University, Plzen,

Prognostic significance of circulating microRNAs in patients with Colorectal Cancer

16:30 – 17:00 COFFEE, POSTERS EXHIBITION

- **17:00-17:30 CHRISTENSEN I, MD, PhD (DENMARK)**
Hvidovre Hospital, Copenhagen

Determination of a multivariable signature for prediction of survival of patients with Colorectal Cancer based on 14 protein biomarkers from 3 cohorts.

- **17:30-17:45 KUCERA R, PhD (CZECH REP)**
University Hospital in Plzen and Faculty of Medicine in Plzen.

New Biomarkers and Mutivariate Analysis in Gastric Cancer Diagnostics

- **17:45-18:00 FEKETE R, MD (ROMANIA)**
Oncology Dep, University of Medicine and Pharmacy, Luliv Hatieganu, Cluj-Napoca
Fluctuations of CEA in the conventional normal range and the risk of relapse in resected CRC

- **18:00-18:30**

MONDAY, NOVEMBER 26. 2018 08:30-13:00, HALL B

SESSION: PANCREATIC CANCER

CHAIRS: KLAPDOR R (GERMANY) IZBICKI JR (GERMANY)

- **08:30-09:00 BLOCK A, PhD, (GERMANY)**
Oncology Dep, University Hospital, Hamburg

Hereditary Pancreatic Cancer

- **09:00-09:30 IZBICKI JR, MD (GERMANY)**
Surgery Dep, University Hospital, Hamburg

Actual and future role of resective surgery in a multidisciplinary and sequential concept of Pancreatic Cancer therapy

- **09:30-10:00 KLAPDOR R, MD (GERMANY)**
University Hospital, Hamburg

Exocrine Pancreatic Cancer- 40 years of clinical experience

- **10:00-10:30 TANIUCHI K, MD (JAPAN)**
Gastroenterology and Hepatology, Kochi Medical School, Kochi University.

CCDC88A mRNA localizing in circulating tumor-derived exosomes as novel serological marker for Pancreatic Cancer

10:30-11:00 COFFEE, POSTERS, EXHIBITION

- **11:00-11:30 KRUGER S, MD (GERMANY)**
Department of Medicine III, University Hospital, LMU Munich.

Therapy prediction and monitoring in Pancreatic Cancer by serial KRAS evaluations

- **11:30-11:45 GERCKENS M (GERMANY)**
Department of Internal Medicine III, University Hospital Munich-Grosshadern, Munich

Interleukin-6 and Interleukin-8 predict overall survival in patients with metastatic Pancreatic Cancer

- **11:45-12:00**

MONDAY, NOVEMBER 26, 2018, HALL A

12:30 - 13:00 ISOBM GA (GENERAL ASSEMBLY)

13:00 – 13:45 LUNCH

13:45 – 14:30 KEY NOTE LECTURE HALL A

KAGAN J, PhD (USA)

Program Director, Cancer Biomarkers Research Group
Division of Cancer Prevention, National Cancer Institute, NIH.

Spatial and Temporal Tumor Atlas – a new approach for development of Cancer Biomarkers and targets for prevention and therapy

MONDAY, NOVEMBER 26, 2018, 14:30-16:30 HALL B

SESSION: MELANOMA

CHAIRS: MARKEL G (ISRAEL) GEBHARDT C (GERMANY)

- **14:30-15:00 MARKEL G, MD, PhD (ISRAEL)**
Head, Immunotherapy for Melanoma Unit, Sheba Medical Center

Novel therapies for Melanoma patients

- **15:00-15:30 GEBHARDT C, MD, PhD (GERMANY)**
Head, Onco-Dermatology, Hamburg University

Diagnosis and differential diagnosis of Melanoma as precondition for adequate therapy

- **15:30-16:00 TREVES A, PhD (ISRAEL)**
Melanoma Center, Sheba Medical Center, Tel Aviv

Cell therapies: from regenerative medicine to Cancer Immunology

- **16:00-16:30 BARAK V, PhD (ISRAEL)**
Head, Immunology Lab for Tumor Diagnosis, Hadassah -University Medical Center, Jerusalem

Biomarkers for assessment of response to new therapies in Melanoma

16:30-17:00 COFFEE, POSTERS, EXHIBITION

17:00-19:00 POSTERS GUIDED SESSION

TUESDAY, NOVEMBER 27, 2018, 08:30-10:30, HALL A

SESSION: PROSTATE CANCER 2

CHAIRS: SEMJONOW A (GERMANY) KUCERA R (CZECH REP.)

- **08:30-09:00 SEMJONOW A, MD (GERMANY)**

Vice Chair, Prostate Center, University Hospital, Münster

Growing evidence in Prostate Cancer screening emphasizes the need for active surveillance

- **09:00-09:30 LOOLJENGA E, PhD (HOLLAND)**

Pathology Dep., Erasmus MC, Rotterdam, Zuid Holland.

Identification and application of (molecular) biomarkers in patients with human Germ Cell Tumors

- **09:30-10:00 -MAKRANZ C, MD (ISRAEL)**

Neuro-Oncology Dep., Hadassah University Medical Center, Jerusalem

Brain-derived circulating DNA as a Biomarker for Radiotherapy-induced brain damage

- **10:00 -10:15 VESELI S, MD (CZECH REP)**

Urology, Charles University 2nd Faculty of Medicine, University Hospital Motol, Prague.

Prostate Health Index Predicts Clinically Significant Prostate Cancer in Final Pathology after Surgical Treatment

- **10:15-10:30 HOLUBECK L, MD, PhD (CZECH REP.)**

Clinical Oncology Dep, Na Homolce Hospital, Prague

Benefit of AV-R7 as treatment selection Marker in patients with metastatic castration resistant Prostate Cancer

10:30 -11:00 COFFEE, POSTERS, EXHIBITION

TUESDAY, NOVEMBER 27, 2018, 11:00-13:00 HALL A

SESSION: BIOBANKING

CHAIRS: ZATLOUKAL K (AUSTRIA) BROCHAUSEN C (GERMANY)

- **11:00-11:30 ZATLOUKAL K, MD, PhD (AUSTRIA)**
Head, European Biobanking Society, MED CAMPUS, Gratz

Pre-analytical standards for Biobanking and Biomarker development

- **11:30-12:00 BECKER K, MD (GERMANY)**
Technical University, Pathology Department, Munich

A Biobanker's view on protein analysis in Clinical tissues

- **12:00-12:30 BROCHAUSEN C, MD, PhD (GERMANY)**
Institute of Pathology, University Regensburg, Regensburg.

- **BROTHER – a unique Bavarian – Czech cooperation to overcome hurdles for Biobank cooperation**

- **12:30-13:00 KINKOROVA J, PhD (CZECH REP.)**
Department of Immunochemistry, University Hospital Plzen.

Biobanking – an important tool for Cancer research

13:00 -13:45 LUNCH

13:45- 14:30 KEY NOTE LECTURE, HALL A

LETOURNEAU C, MD, PhD (FRANCE)
Head, Department of Drug Development and Innovation, Institute Curie,
Paris & Saint-Cloud

Precision Medicine in Oncology

TUESDAY, NOVEMBER 27 2018, 08:30-13:00, HALL B

SESSION: LUNG CANCER

CHAIRS: MOLINA R (SPAIN) NECHUSHTAN H (ISRAEL)

- 08:30-09:00 NECHUSHTAN H, MD, PhD (ISRAEL)

Head, Lung Cancer Unit, Hadassah -University Medical Center, Jerusalem.

New combined therapies for Lung Cancer.

- 09:00-09:30 MOLINA R, MD, PhD (SPAIN)

Head, Laboratory Hospital Clinic, Oncobiology Unit, University of Barcelona

**Tumor Markers Algorithm helping in the diagnosis / histological diagnosis of Lung Cancer-
results of a multicentric study**

- 09:30-10:00 HOLDENRIEDER S, MD, PhD (GERMANY)

Head, Institute of Laboratory Medicine, German Heart Center, Technical University, Munich

Multi parametric approaches for diagnosis and monitoring of Lung Cancer

- 10:00-10:30 AGUR Z, PhD (ISRAEL)

OPTIMATA LTD, and Institute for Medical BioMathematics

**A New Algorithm Predicting Imminent Disease Progression in Advanced Non-Small cell Lung
Cancer Patients by Applying Machine- Learning to Multiple Tumor Markers**

10:30 -11:00 COFFEE, POSTERS, EXHIBITION

- **11:00-11:30** **ROSSUM V H, MD (HOLLAND)**

Department of Laboratory Medicine, The Netherlands Cancer Institute

Design of biomarker-response based medical test for early prediction of Nivolumab non-responsiveness in metastatic Non-Small Cell Lung Cancer patients

- **11:30-12:00** **DIETEL M, MD (GERMANY)**

Head, Pathology Department, Charite University, Berlin.

Predictive molecular Pathology

- **12:00- 12:30** **CREE I, PhD (UK)**

International Agency for Research on Cancer (IARC), World Health Organization

Gap analysis in Pathology

- **12:30- 13:00** **HALLENSLEBEN K, PhD (GERMANY)**

GEFAT-IT GmbH, Geschäftsleitung IT – Oldendorf.

Flexible and sustainable Data Management for Biobanks

13:00 -13:45 LUNCH

13:45- 14:30 KEY NOTE LECTURE, HALL A

LETOURNEAU C, MD, PhD (FRANCE)

Head, Department of Drug Development and Innovation, Institute Curie,
Paris & Saint-Cloud

Precision Medicine in Oncology

TUESDAY, NOVEMBER 27, 2018, 14:30-16:30, HALL A

LYMPHOMA, LEUKEMIA, MM SESSION

CHAIRS: CHAPMAN C (UK) STIGBRAND T (SWEDEN)

- **14:30-15:00 SELL S (USA)**

New York State Department of Health, Wadsworth Center

Differentiation therapy of Myeloid Leukemia

- **15:00-15:30 ERIKSSON S, PhD (SWEDEN)**

AroCell AB, Uppsala

TK-210, a new marker for Lymphoma, Leukemia and MM

- **15:30-15:45 PRADHAN T, PhD (INDIA)**

Cancer Research Program 4, Rajiv Gandhi Center for Biotechnology, Trivandrum, Kerala.

Role of the STIL gene in Colorectal Cancer Stem Cells

- **15:45 -16:00 NOVAK V, MD (CZECH REP.)**

Urology, Charles University, 2nd Faculty of Medicine University Hospital Motol, Prague.

The Level of Serum Thymidine Kinase 1 Correlates with the Presence of Prostate Cancer.

16:00- 16:30 CLOSING CEREMONY AND AWARDS

16:30 -17:00 COFFEE, POSTERS, EXHIBITION